Annette von Delft

Annette von Delft is the Head of Anti-Infective Pillar at the Centre for Medicines Discovery (CMD), University of Oxford. She oversees discovery and development projects on novel small molecules against viruses, bacteria and fungi, from initial target validation to preclinical development. Annette trained as a clinician at University of Leipzig (Germany) and Oxford University Hospitals (UK), and obtained a DPhil in Clinical Medicine from the University of Oxford, working on HCV T cell immunology and vaccine development.  

Annette's current focus is developing novel antivirals for pandemic preparedness. She leads the preclinical development of coronavirus small molecules for the global consortia COVID Moonshot and the ASAP AVIDD Center on behalf of Drugs for Neglected Disease initiative (DNDi). She is the clinical lead for discovery projects targeting flavi-, entero-, and influenza viruses, supported by the Wellcome Trust, NIH NIAID, PAD (Novo Nordisk and Gates Foundations), and the Cumming Global Centre for Pandemic Therapeutics. She also coordinates a portfolio of early discovery projects against antimicrobial and fungal targets.